Can plasma exchange therapy induce regulatory T lymphocytes in multiple sclerosis patients?

Clinical and Experimental Immunology

Volumn 168, Issue 1, 2012, Pages 75-77

  Jamshidian, A ^a   Gharagozloo, M ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Multiple sclerosis; Plasma exchange; Regulatory T cell

Indexed keywords

ADAPTIVE IMMUNITY; ARTICLE; AUTOIMMUNITY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTE FUNCTION; MULTIPLE SCLEROSIS; PLASMAPHERESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REMISSION; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

AUTOIMMUNE DISEASES; HUMANS; MULTIPLE SCLEROSIS; MYELIN SHEATH; PLASMA EXCHANGE; PLASMAPHERESIS; T-LYMPHOCYTES, REGULATORY;

EID: 84857699935     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04547.x     Document Type: Article

References (26)

1. Tumani H. Corticosteroids and plasma exchange in multiple sclerosis. J Neurol 2008; 255:36-42.
2. Kaynar L, Altuntas F, Aydogdu I etal. Therapeutic plasma exchange in patients with neurologic diseases: retrospective multicenter study. Transfus Apher Sci 2008; 38:109-15.
3. Szczepiorkowski ZM, Bandarenko N, Kim HC etal. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apheresis 2007; 22:106-75.
4. Dau PC. Increased proliferation of blood mononuclear cells after plasmapheresis treatment of patients with demyelinating disease. J Neuroimmunol 1990; 30:15-21.
5. Dau PC, Callahan JP. Immune modulation during treatment of systemic sclerosis with plasmapheresis and immunosuppressive drugs. Clin Immunol Immunopathol 1994; 70:159-65.
6. De Luca G, Lugaresi A, Iarlori C etal. Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1999; 95:190-4.
7. Goto H, Matsuo H, Nakane S etal. Plasmapheresis affects T helper type-1/T helper type-2 balance of circulating peripheral lymphocytes. Ther Apher 2001; 5:494-6.
8. Kambara C, Matsuo H, Fukudome T, Goto H, Shibuya N. Miller Fisher syndrome and plasmapheresis. Ther Apher 2002; 6:450-3.
9. Yoshii F, Shinohara Y. Lymphocyte subset proportions in Guillain-Barré syndrome patients treated with plasmapheresis. Eur Neurol 2000; 44:162-7.
10. Yeh JH, Chien PJ, Hsueh YM, Shih CM, Chiu HC. Changes in the lymphocyte subset after double-filtration plasmapheresis. Am J Clin Pathol 2007; 128:940-4.
11. Steven MM, Tanner AR, Holdstock GE etal. The effect of plasma exchange on the in-vitro monocyte function of patients with immune complex diseases. Clin Exp Immunol 1981; 45:240-5.
12. Shariatmadar S, Nassiri M, Vincek V. Effect of plasma exchange on cytokines measured by multianalyte bead array in thrombotic thrombocytopenic purpura. Am J Hematol 2005; 79:83-8.
13. Dau PC. Increased antibody production in peripheral blood mononuclear cells after plasma exchange therapy in multiple sclerosis. J Neuroimmunol 1995; 62:197-200.
14. Yeh JH, Wang SH, Chien PJ, Shih CM, Chiu HC. Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravis. Eur J Neurol 2009; 16:1318-22.
15. Tesar V, Jelinkova E, Jirsa M Jr, Bakosova M, Pitha P, Chabova V. Soluble adhesion molecules and cytokines in patients with myasthenia gravis treated by plasma exchange. Blood Purif 2000; 18:115-20.
16. Tesar V, Jelinkova E, Masek Z etal. Influence of plasma exchange on serum levels of cytokines and adhesion molecules in ANCA-positive renal vasculitis. Blood Purif 1998; 16:72-80.
17. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000; 101:455-8.
18. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains [CD25]. Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151-64.
19. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199:971-9.
20. Venken K, Hellings N, Thewissen M etal. Compromised CD4+ CD25[high] regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 2008; 123:79-89.
21. Haas J, Hug A, Viehover A etal. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol 2005; 35:3343-52.
22. Barath S, Soltesz P, Kiss E etal. The severity of systemic lupus erythematosus negatively correlates with the increasing number of CD4+CD25[high]FoxP3+ regulatory T cells during repeated plasmapheresis treatments of patients. Autoimmunity 2007; 40:521-8.
23. Baxter A, Hodgkin P. Activation rules: the two-signal theories of immune activation. Nat Rev Immunol 2002; 2:439-46.
24. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14:233-58.
25. Chang CH, Furue M, Tamaki K. B7-1 expression of Langerhans cells is up-regulated by proinflammatory cytokines, and is down-regulated by interferon-gamma or by interleukin-10. Eur J Immunol 1995; 25:394-8.
26. Freedman AS, Freeman GJ, Rhynhart K, Nadler LM. Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol 1991; 137:429-37.